本报讯 （记者金婉霞）7月31日，申联生物医药（上海）股份有限公司（以下简称"申联生物"）公告 称，近日，公司与中国农业科学院兰州兽医研究所（以下简称"兰研所"）等单位签订了项目合同，拟共 同开发猪用口蹄疫等三种疫病多联多价疫苗及牛用口蹄疫等三种疫病多联多价疫苗，合作各方按照协议 约定任务和分工，各自承担相关费用，合作研发项目产生的技术成果及知识产权归公司及兰研所两方共 同享有。 （编辑 张文玲 郭之宸） 申联生物方面表示，拟开发的疫苗预期可实现"一针四防"，有效减少免疫次数，节约免疫资源和防疫成 本，提升生产效率，具备较强的市场竞争力，将有助于公司为客户提供更全面、高效的疫病防控解决方 案，将进一步提升公司在动保领域的技术领先地位。未来，申联生物将持续加强与兰研所的深度合作， 紧跟行业发展趋势，精准把握流行毒株变化和临床需求，进一步挖掘研发技术平台体系的应用潜力，加 速推进其他多联多价疫苗、mRNA疫苗、合成肽疫苗、病毒样颗粒（VLPs）疫苗等新产品的技术突破 与产业化落地，在猪用、反刍用、宠物用、水产用等疫病防治领域逐步形成集群化产品矩阵，不断提升 公司核心竞争力。 ...

Major Events - Water Well Square: Director Sathish Krishnan resigned due to work reasons, and will no longer hold any position in the company [1] - Victory Energy: The company reported normal operating conditions with no significant changes in the internal and external business environment [1] Investments - Dream Network Technology: The company plans to jointly invest in a private equity fund with a target fundraising scale of 2 billion yuan, with the company contributing 50 million yuan [2] - Guoen Co., Ltd.: The company has completed the development of PEEK material production technology and aims to establish a vertical integration platform for the entire PEEK industry chain [2] Performance - Action Education: The controlling shareholder proposed a mid-term dividend of 10 yuan per 10 shares for the 2025 fiscal year [3] - Jiejia Weichuang: The company expects a net profit of 1.7 billion to 1.96 billion yuan for the first half of 2025, representing a year-on-year increase of 38.65% to 59.85% [3] - Sinopec: The company anticipates a net profit of 20.1 billion to 21.6 billion yuan for the first half of 2025, a decrease of 39.5% to 43.7% year-on-year due to various market pressures [4] - Daodaquan: The company reported a net profit of 181 million yuan for the first half of 2025, a year-on-year increase of 563.15% [4] - New Light Optoelectronics: The company expects a loss of 19 million to 23 million yuan for the first half of 2025, with revenue declining significantly [4] Contracts and Collaborations - Shunlian Bio: The company signed contracts for the development of multi-valent vaccines in collaboration with the Chinese Academy of Agricultural Sciences [4] - Boying Special Welding: The company signed a cooperation framework agreement with Suzhou Weirhan to collaborate in special welding technology applications [5] Shareholding Changes - Jiangnan Yifan: The company's director and general manager plans to increase shareholding by purchasing between 50,000 and 100,000 shares from August 1, 2025, to January 31, 2026 [6]

Core Viewpoint - The company, Shenlian Biological (688098.SH), has signed cooperative contracts with the Lanzhou Veterinary Research Institute of the Chinese Academy of Agricultural Sciences and other entities to develop multi-valent vaccines for swine and cattle, focusing on several significant diseases [1] Group 1: Vaccine Development Contracts - The company has entered into two contracts for the technical development of vaccines: one for swine diseases including foot-and-mouth disease (O-type/A-type), swine fever, and pseudorabies, and another for cattle diseases including foot-and-mouth disease (O-type/A-type), viral diarrhea/mucosal disease, and infectious bovine rhinotracheitis [1] - The collaboration involves shared responsibilities and costs among the parties according to the agreements, with the resulting technological achievements and intellectual property being jointly owned by the company and the Lanzhou Veterinary Research Institute [1]

Core Viewpoint - The company, Shenlian Biological (688098), has signed cooperative contracts with the Lanzhou Veterinary Research Institute of the Chinese Academy of Agricultural Sciences to develop multi-valent vaccines for swine and cattle diseases [1] Group 1: Vaccine Development Contracts - The company has entered into two contracts for the technical development of vaccines: one for swine diseases including foot-and-mouth disease (O-type/A-type), swine fever, and pseudorabies, and another for cattle diseases including foot-and-mouth disease (O-type/A-type), viral diarrhea/mucosal disease, and infectious bovine rhinotracheitis [1] - The collaboration involves shared responsibilities and costs among the parties involved, with the resulting technological achievements and intellectual property being jointly owned by the company and the Lanzhou Veterinary Research Institute [1]

Core Viewpoint - The company has signed cooperative contracts with the Lanzhou Veterinary Research Institute of the Chinese Academy of Agricultural Sciences and other units to develop multi-valent vaccines for swine and cattle, focusing on several significant diseases [1] Group 1: Vaccine Development Contracts - The company has entered into a contract for the technical development of a tri-valent vaccine for swine, targeting foot-and-mouth disease (FMD) types O and A, swine fever, and pseudorabies [1] - Additionally, a contract has been signed for the development of a tri-valent vaccine for cattle, addressing FMD types O and A, viral diarrhea/mucosal disease, and infectious bovine rhinotracheitis [1] - The collaboration involves shared responsibilities and costs among the parties, with the resulting technological achievements and intellectual property being jointly owned by the company and the Lanzhou Veterinary Research Institute [1]

申联生物公告，公司与中国农业科学院兰州兽医研究所等单位签订了《猪口蹄疫O型/A型、猪瘟、伪狂 犬病三联疫苗技术开发（合作）合同》及《牛口蹄疫O型/A型、病毒性腹泻/黏膜病、传染性鼻气管炎三 联疫苗技术开发（合作）合同》，共同开发猪用口蹄疫等三种疫病多联多价疫苗及牛用口蹄疫等三种疫 病多联多价疫苗。合作各方按照协议约定任务和分工，各自承担相关费用，合作研发项目产生的技术成 果及知识产权归公司及兰研所两方共同享有。 ...